A5023476154- Cardiac Valve Diseases and Treatments
- Cardiovascular Function and Risk Factors
- Cardiac and Coronary Surgery Techniques
- Cardiac, Anesthesia and Surgical Outcomes
- Heart Failure Treatment and Management
- Cardiovascular Issues in Pregnancy
- Cardiac Imaging and Diagnostics
- Aortic Disease and Treatment Approaches
- Infective Endocarditis Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Diabetes Treatment and Management
- Cardiovascular Disease and Adiposity
- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Congenital Heart Disease Studies
- Cardiac Structural Anomalies and Repair
- Pulmonary Hypertension Research and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiomyopathy and Myosin Studies
- Infectious Aortic and Vascular Conditions
- Cardiovascular Effects of Exercise
- Rheumatoid Arthritis Research and Therapies
- Aortic aneurysm repair treatments
- Metabolomics and Mass Spectrometry Studies
- Cardiac Arrhythmias and Treatments
Universidade do Porto
2016-2025
Faculdade de Medicina do ABC
2023
British Heart Foundation
2022
University of Leeds
2022
Hospital da Luz
2021
Centro Hospitalar do Porto
2021
Discovery Air (Canada)
2021
Jagiellonian University
2017
Hospital de São João
2015
OBJECTIVE Patients with type 2 diabetes (T2D) have a high risk for developing heart failure (HF), which is associated poor prognosis. Fenofibrate may reduce HF events through multiple mechanisms. We sought to study the effect of fenofibrate (vs. placebo) in outcomes among patients T2D receiving simvastatin enrolled Action Control Cardiovascular Risk Diabetes lipid trial (ACCORD Lipid). RESEARCH DESIGN AND METHODS used Cox regression analysis background glucose-lowering strategy as...
Heart failure (HF) is among the leading causes of morbidity and mortality worldwide. Several conditions trigger left ventricular chronic pressure or volume overload, hypertrophy, systolic diastolic dysfunction, to cardiac remodeling a rapid progression toward HF. Therapeutic interventions elicit reverse (RR), highly variable myocardial response that ranges from none total structural/functional recovery. However, HF patients present several comorbidities medications mask comprehensive...
Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent but still poorly understood clinical entity. Its current pathophysiological understanding supports critical role of comorbidities and their chronic effect on cardiac function structure. Importantly, despite the replication some HFpEF phenotypic features, to this day, experimental models have failed bring new effective therapies setting. Thus, direct investigation human myocardial samples may unveil key, possibly...
This study describes the impact of cardiovascular risk factors (CVR) in pregnancy-induced remodeling and postpartum reverse (up to 1 yr) by applying advanced statistic methods (multivariate generalized linear mixed-effects models) a prospective cohort pregnant women. Aiming extrapolate pathological conditions, this invaluable “human model” allowed us demonstrate that arterial hypertension is critical CVR for worse RR ST2/IL33-receptors CRP are potential biomarkers hypertrophy reversal.
New models of aortic bioprostheses have proven excellent early haemodynamic profile, but their mid and long-term performance warrants further systematic assessment. The aim this study is to report clinical St. Jude Medical Trifecta bioprosthesis during 5 years implantation.We performed a single centre, retrospective, observational descriptive including all 556 individuals who underwent valve replacement (AVR) with the (between July 2011 June 2016). Survival re-intervention were censored in...
Assessing reversibility of pulmonary vascular changes through vasoreactivity testing (VRT) optimizes end-stage heart failure patient selection for transplant. All efforts should be made to unload the left ventricle and reduce resistance effectively exclude irreversible hypertension. We reviewed our centre's cardiac transplant registry database (2009-2017) VRT compared haemodynamic responses with 40 ppm inhaled NO (n = 14), 14-17 μg iloprost 7), 24 h 0.1 μg/kg/min intravenous levosimendan...
Abstract Introduction Recurrence of atrial fibrillation (AF) within the blanking period after catheter ablation (CA) is traditionally classified as a transient and benign event. However, recent findings suggest that early recurrence (ER) associated with late (LR), challenging predefined “blanking period”. We aimed to determine clinical procedural predictors ER LR CA establish risk in patients who experience ER. Methods Results Retrospective single‐centre study including all underwent first...